We are live on
!
Find out more
SI
Sofinnova Investments Portfolio holdings
AUM
$2.63B
1-Year Est. Return
117.41%
This Fund
S&P 500
This Quarter
Est. Return
+8.88%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$664M
(-35%)
Cap. Flow
-$732M
Cap. Flow
% of AUM
-58.11%
Top 10 Holdings %
Top 10 Hldgs %
59.75%
Holding
95
New
14
Increased
22
Reduced
15
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIOA
BioAge Labs
BIOA
|
+$46.2M |
| 2 |
Incyte
INCY
|
+$45.5M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$22.7M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$20.7M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$13.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$100M |
| 2 |
Stryker
SYK
|
+$65.7M |
| 3 |
Align Technology
ALGN
|
+$52.8M |
| 4 |
Intuitive Surgical
ISRG
|
+$38.8M |
| 5 |
Edwards Lifesciences
EW
|
+$37.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
Intuitive Surgical
ISRG
$128B
| – | – |
-87,217
| Closed | -$38.8M |
|
|
77
PUT
Intuitive Surgical
ISRG
$128B
| – | – |
-50,000
| Closed | -$22.2M |
|
78
LivaNova
LIVN
$4.43B
| – | – |
-20,602
| Closed | -$1.13M |
|
|
MASI
79
DELISTED
Masimo
MASI
| – | – |
-20,161
| Closed | -$2.54M |
|
80
Madrigal Pharmaceuticals
MDGL
$12.7B
| – | – |
-44,417
| Closed | -$12.4M |
|
81
PDS Biotechnology
PDSB
$38.7M
| – | – |
-142,635
| Closed | -$418K |
|
82
PepGen
PEPG
$131M
| – | – |
-561,128
| Closed | -$8.96M |
|
83
Insulet
PODD
$11.4B
| – | – |
-60,967
| Closed | -$12.3M |
|
84
PUT
Invesco QQQ Trust
QQQ
$449B
| – | – |
-400,000
| Closed | -$192M |
|
85
Roivant Sciences
ROIV
$25B
| – | – |
-1,868,412
| Closed | -$19.7M |
|
86
Sarepta Therapeutics
SRPT
$1.68B
| – | – |
-195,852
| Closed | -$30.9M |
|
87
PUT
Savara
SVRA
$1.11B
| – | – |
-150,000
| Closed | -$605K |
|
|
88
Stryker
SYK
$129B
| – | – |
-193,084
| Closed | -$65.7M |
|
89
Teleflex
TFX
$5.8B
| – | – |
-13,649
| Closed | -$2.87M |
|
90
Waters Corp
WAT
$36.4B
| – | – |
-21,804
| Closed | -$6.33M |
|
91
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
| – | – |
-250,000
| Closed | -$23.2M |
|
92
Zimmer Biomet
ZBH
$17.8B
| – | – |
-10,630
| Closed | -$1.15M |
|
93
Kyverna Therapeutics
KYTX
$481M
| – | – |
-47,850
| Closed | -$359K |
|
|
AXNX
94
DELISTED
Axonics, Inc. Common Stock
AXNX
| – | – |
-150,490
| Closed | -$10.1M |
|
|
MRNS
95
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| – | – |
-104,700
| Closed | -$122K |
|
Similar funds
WWM
ACI
LOAMS
IA
WCA
ACM
NIG
WBG
Sofinnova Investments's Q3 2024 Portfolio in Review
As of Q3 2024, Sofinnova Investments held 95 positions worth $1.26B, down 35% from $1.92B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Sofinnova Investments withdrew a net $732M in Q3 2024, closing 35 positions and reducing 15 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $100M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 82% a quarter earlier.
Against the trend, Sofinnova Investments opened a new position in BioAge Labs worth $47.9M.
- Sofinnova Investments's largest Q3 2024 buy was BioAge Labs: 2,304,901 shares worth $47.9M.
- Sofinnova Investments added most to IDEAYA Biosciences in Q3 2024, an estimated $22.7M increase.
- Sofinnova Investments's biggest Q3 2024 reduction was Edwards Lifesciences, cutting an estimated $37.9M.
- Sofinnova Investments fully exited Ascendis Pharma A/S in Q3 2024, selling an estimated $100M.
- Sofinnova Investments's ten largest holdings make up 60% of its $1.26B portfolio in Q3 2024.
- Sofinnova Investments opened 14 new positions and closed 35 in Q3 2024.
- Sofinnova Investments's portfolio value fell 35% quarter-over-quarter to $1.26B.
Based on Sofinnova Investments's 13F filing for Q3 2024, filed 13 Nov 2024.